The role of vitamin D supplementation in augmenting IFN-γ production in response to mycobacterium tuberculosis Infection: A randomized controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The purpose of the research was to see if giving the vitamin D supplements to TB patients affected their prognosis.

Why It Was Studied

Vitamin D supports the immune system fight TB by inhibiting Interferon-gamma (IFN-γ) and lowering host inflammation.

The statistical analysis used descriptive statistics (mean and standard deviation), Friedman's test and Fisher's test.

Who Took Part

The study group was 200 patients.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

IFN-γ responses to whole blood stimulation generated by the Mycobacterium tuberculosis sonicate (MTBs) antigen and early secreted and T cell activated 6 kDa (ESAT6) were assessed at 0 and 12 weeks.

What Was Measured

The statistical analysis used descriptive statistics (mean and standard deviation), Friedman's test and Fisher's test.

Topics PubMed links to this paper include Vitamins, Tuberculosis, Vitamin D, Mycobacterium tuberculosis, Dietary Supplements and Interferon-gamma.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 200 patients.

The publication is from 2023 (Pakistan journal of pharmaceutical sciences), a journal based in Pakistan.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.